Effects of Losartan Potassium on Serum Uric Acid in Patients with Chronic Glomerulonephritis
Losartan potassium is a angiotensin II receptor antagonist, which can be combined with angiotensin II receptor 1 to prevent the binding of angiotensin to receptor, thereby it can block the biological effects mediated by angiotensin II, dilat the efferent glomerular arteriole obviously, improve the selectivity and permeability of glomerular filtration membrane, and reduce the production of albuminuria to protect the kidney. Compared with other drugs, losartan potassium inhibits the urate transporter and acts directly on the proximal glomeruli, and can increase the excretion of sodium. The excretion of uric acid is closely related to the transport of sodium, thus it can reduce the content of serum uric acid.
The significance of losartan potassium in the treatment of chronic glomerulonephritis is the multiplicity of the therapeutic effect. It can reduce the blood pressure and the level of urine protein effectively and smoothly, and reduce the content of serum uric acid obviously, and achieve the goal of protecting the kidney. Therefore, for patients with chronic glomerulonephritis complicated with hyperuricemia, losartan potassium can achieve good therapeutic effect, it is recommended to promote the use of clinical. Therefore, for patients with chronic glomerulonephritis complicated with hyperuricemia, using losartan potassium can achieve good therapeutic effect, and it is recommended to be popularized in clinic.